Duke's Poliovirus Therapy Wins "Breakthrough" Status | The ... Debbie Puffer, 61, has been a patient at Duke University since 2014 when doctors began treating her deadly brain cancer, glioblastoma, with a most unlikely weapon: poliovirus. His work has received a wealth of attention from the oncology research community and was featured on CBS's 60 Minutes twice ( March 2015 and May 2016 ). Overview: Our laboratory is pursuing a comprehensive analysis of the biology and therapy of adult and childhood central nervous system malignancies, particularly high-grade medulloblastoma, glioma, and ependymoma. Regional Oncolytic Poliovirus ... - United States Army Breakthrough Status 12:32. Brain Cancer Trial Given Breakthrough Status by FDA Duke Clinical & Translational Science Institute In colloboration with the Division of Neurology and the Department of Pathology, clinical and laboratory trials have been initiated to identify better treatment for this condition. Notably, this study at Duke University gained notoriety beginning in 2015 when it was the subject of a two-part story on CBS News' 60 minutes. Professor and director of the Preston Robert Tisch Brain Tumor Center at Duke University. In 2015, a team of researchers at Duke University was launched into the spotlight by CBS news show 60 Minutes, which devoted a two-part segment to research aimed at turning poliovirus into a . Principal researchers at Duke who have been involved in the development and testing of the poliovirus therapy have founded and invested in a start-up company to advance the research. The oncolytic poliovirus therapeutic approach has shown such promising results in patients with glioblastoma, that it was recently featured on a on a special two-segment program of 60 Minutes. The treatment involves injecting poliovirus—genetically modified to be harmless to normal cells—directly into a brain tumor. Results in the earliest stage of testing have been so remarkable . Henry Seth Friedman. They were referring to a new "breakthrough" treatment for glioblastoma, the deadly cancer the Tragically Hip frontman has, that had been profiled on the show 60 Minutes in 2015 and last month. A phase 1 trial of a therapy developed by researchers at the Preston Robert Tisch Brain Tumor Center shows significantly improved long-term survival for patients with recurrent glioblastoma. 047 Baker House, DUMC 3624, Durham, NC 27710 annick.desjardins@duke.edu (919) 684-5301 By Sarah Avery. Debra Puffer, a 61-year-old resident of Rome, NY, was diagnosed with glioblastoma in 2014 and was treated with surgery, chemo and radiation. Duke researchers are now studying the effects of this therapy on other cancers. The next clinical step will be to combine both the virus and the immunotoxin with anti-PD1, an immune checkpoint blockade inhibitor and with anti-CD40, a fully human monoclonal antibody which converts . Comparatively, just 4 percent of patients with the same type of recurring brain tumors were alive at three years when undergoing the previously available . A bold experiment to kill a vicious form of brain cancer has been granted breakthrough status by the Food and Drug Administration. Researchers at Duke first discovered that the poliovirus delivered directly into intracranial tumors was able to trigger a positive immune reaction, which led to a longer survival rate from the . A glioblastoma therapy touted in a "60 Minutes" report that aired Sunday evening, focusing on the use of the polio virus to treat glioblastoma, isn’t a particularly new idea and results are . The virus latches onto cancer cells and activates the body's immune system to attack the tumor. We believe that regional tumor-targeted cytotoxic therapies, such as the . Duke Breakthrough Cancer Treatment to be featured on CBS 60 Minutes this Sunday, May 15 Watch CBS 60 Minutes this Sunday, May 15 (CBS, 7 p.m., Eastern) for the latest news about the FDA granting breakthrough status to the investigational modified poliovirus cancer therapy developed at Duke to treat glioblastoma. Meanwhile, the . Now, with funding from the Duke CTSA through the Duke Translational Research Institute (DTRI) Collaborative Pilot Award, an interdisciplinary team of researchers is on the path Now, with funding from the Duke CTSA through the Duke Translational Research Institute (DTRI) Collaborative Pilot Award, an interdisciplinary team of researchers is on the path to apply this . In a poignant, two-part segment May 15, 2016, CBS's 60 Minutes returned to Duke to update viewers on the poliovirus therapy developed and tested by researchers at the Preston Robert Tisch Brain Tumor Center. The material consisted of representative FFPE glioblastoma sections, of which 34, 27, and 2 were from surgeries for newly diagnosed, recurrent, and progressive disease, respectively, at Duke University Medical Center (Table 1). Since the news program "60 Minutes" first aired two segments in March 2015 focused on an early-phase clinical trial taking place at Duke University, a lot of excitement has been generated about the investigational treatment highlighted: PVS-RIPO - more commonly referred to as the re-engineered poliovirus.. This new status from the FDA will fast-track the promising treatment so hundreds of . A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. When the cancer returned again, she got a "booster" infusion of the polio virus last August. 1. In an interview with Scott Pelley, Duke Surgery's Dr. Smita Nair discusses how this therapy remarkably reduces breast cancer tumors in mice. Highlighting the efforts of Duke University scientists to turn a once-feared viral foe into an ally, 60 Minutes correspondent . The poliovirus therapy showed a three-year survival benefit of 21 percent. Duke researchers made a big splash in the news last spring when 60 Minutes featured the success of early clinical trials using a modified poliovirus in the fight against a deadly form of brain cancer. A genetically modified polio virus improved the longer-term survival of patients with a lethal type of brain tumor, according to the results of an early-stage clinical trial published Tuesday. Duke researchers made a big splash in the news last spring when 60 Minutes featured the success of early clinical trials using a modified poliovirus in the fight against a deadly form of brain cancer. Photos by Shawn Rocco/Duke Health News OfficeIn a poignant, two-part segment May 15, CBS's 60 Minutes returned to Duke to update viewers on the poliovirus therapy developed and tested by researchers at the Preston Robert Tisch Brain Tumor Center. In his new blog, Mr. Bacha discusses the 60 Minutes update on its spring 2015 story on Duke University's experimental brain cancer treatment, which was recently granted "breakthrough therapy status" by the US FDA, which uses the polio vaccine to turn on an immune response against brain cancer. In an interview with Scott Pelley, Duke Surgery's Dr. Smita Nair discusses how this therapy remarkably reduces breast cancer tumors in mice. Scientists at Duke are testing a modified form of the polio virus to treat glioblastoma, and the reason for the 60 Minutes update was that the research has recently been granted "breakthrough . That process seems to be what makes cancer cells vulnerable to an ongoing immune attack. Patients harboring glioblastoma, the most malignant primary brain tumor, have a life expectancy of less than one year. Duke recently tested the safety of this oncolytic poliovirus in a phase I clinical trial of patients with recurrent glioblastoma. The approach got widespread attention in 2015 when it was covered by the CBS program "60 Minutes." The. My career is dedicated to unraveling RNA virus:host relations and devising methods of exploiting them for cancer immunotherapy and vaccine design. My background is in translation regulation and mRNA . The next clinical step will be to combine both the virus and the immunotoxin with anti-PD1, an immune checkpoint blockade inhibitor and with anti-CD40, a fully human monoclonal antibody which converts . Since the news program "60 Minutes" first aired two segments in March 2015 focused on an early-phase clinical trial taking place at Duke University, a lot of excitement has been generated about the investigational treatment highlighted: PVS-RIPO - more commonly referred to as the re-engineered poliovirus. At first, she was . Duke Box 3624, Durham, NC 27710 The Preston Robert Tisch Brain, Rm. Scott Pelley of "60 Minutes" interviews Duke neuro-oncologists Dr. Annick Desjardins and Dr. Henry Friedman. Twen… <p>Debbie Puffer, 61, has been a patient at Duke University since 2014 when doctors began treating her deadly brain cancer, glioblastoma, with a most unlikely weapon: poliovirus. Distinguished Professor of Pediatric Oncology, in the School of Medicine. The virus latches onto cancer cells and. . The re-engineered virus prompted a powerful immune response against the viral-infected cancer cells, which in some patients . The CBS show 60 Minutes airs "Killing Cancer" on March 29, 2015, introducing the Duke University polio vaccine being used to eradicate glioblastomas, which involves injecting a genetically modified polio virus directly into a brain tumor. In an excerpt for an upcoming "60 Minutes" report, Scott Pelley looks at how Duke University researchers are reengineering the polio virus to attack glioblastoma. Just to recap, on March 29, 60 Minutes ran a two-segment profile of Duke University molecular biologist Matthias Gromeier, who engineered the polio virus so that it would kill glioblastoma cells. Note: On May 15, CBS's 60 Minutes updated viewers on poliovirus therapy for glioblastoma. With the release of their data, Gromeier and colleagues sparked . When the cancer came back, she got the polio virus therapy at Duke and went 2.5 years without a recurrence. So I was surprised to read a recent t article in Science Translational Medicine about experiments at Duke University treating cancer in human cells and in mice with an engineered poliovirus, when. A 60 Minutes Episode featured how polio vaccines fight cancer: A better quality of life The Istari technology does not have the nasty side-effects of many current cancer treatments such as . FDA grants breakthrough status to Duke cancer therapy. Researchers at Duke first discovered that the poliovirus delivered directly into intracranial tumors was able to trigger a positive immune reaction, which led to a longer survival rate from the . Duke researchers made a big splash in the news last spring when 60 Minutes featured the success of early clinical trials using a modified poliovirus in the fight against a deadly form of brain cancer. Duke researchers made a big splash in the news last spring when 60 Minutes featured the success of early clinical trials using a modified poliovirus in the fight against a deadly form of brain cancer. "Glioblastoma is the most . Stephanie Lipscomb One of those patients was . UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham . HealthNewsReview.org ran a critique of that story . After two years, the poliovirus group started faring better. While recurrent glioblastoma is the first planned indication and the primary focus for now, research is ongoing at Duke to explore the potential of the modified poliovirus for other solid tumor cancers, including advanced prostate and pancreatic cancer. "60 Minutes" has been following patients in the clinical trial for the last two years. University Hospitals (UH) Seidman Cancer Center treated its first patient in a new clinical trial to validate the . Gromeier is the principal investigator of the Duke trial evaluating the poliovirus for GBM that was featured on 60 Minutes in March. Glioblastoma, among the deadliest of human cancers, is at the center of this week's two-part 60 Minutes report. The therapy, based on a genetically modified . Because of UH Cleveland Medical Center's significant brain tumor program, immunotherapy expertise and experience as a research center, trial sponsors Istari Oncology and Duke University chose University Hospitals as one of a select number of research sites for the Phase II study. UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham, NC. CBS' "60 Minutes" looks at the polio virus as a treatment for brain cancer in a Scott Pelley report this weekend. My career is dedicated to unraveling RNA virus:host relations and devising methods of exploiting them for cancer immunotherapy and vaccine design. My background is in translation regulation and mRNA . Last night's 60 Minutes featured Duke's poliovirus therapy for glioblastoma, which the FDA has deemed a "breakthrough therapy." Duke researchers are now studying the effects of this therapy on other cancers. Jeff Fager tells 60 Minutes Overtime that he wished his dad had lived long enough to see the story. "One of the scientists told me it takes a killer to kill a killer. Editor's Note: For more information on the Duke University polio trial or other . The excitement was well-warranted, as the results reported at the time showed that .